Sign In
Last checked at 
15 Sep 2017 07:00
15 September 2017
Oxford BioDynamics Plc
Directorate update
Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to announce that further to the announcement on 30 June 2017, Paul Stockdale will join the Company as Chief Financial Officer and an Executive Director on the Board, with immediate effect.
For further details contact:
Oxford BioDynamics Plc |
| +44 (0)1865 518910 |
Christian Hoyer Millar, CEO |
|
|
Paul Stockdale, CFO |
|
|
|
|
|
Stifel Nicolaus Europe Limited |
| +44 (0)20 7710 7600 |
Nominated Advisor and Broker |
|
|
David Arch |
|
|
Jonathan Senior |
|
|
Peter Lees |
|
|
Ben Maddison |
|
|
|
| |
Shore Capital |
| +44 (0)20 7408 4090 |
Joint Broker |
|
|
Bidhi Bhoma |
|
|
Edward Mansfield |
|
|
| ||
FTI Consulting |
| +44 (0)20 3727 1000 |
Financial Public Relations Advisor |
|
|
Julia Phillips |
|
|
Brett Pollard |
|
|
Natalie Garland-Collins |
|
|
Appendix - Schedule Two Information
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Paul Leslie Stockdale, aged 42 years, has been a director of the following companies during the five years preceding the date of this announcement:
Current directorships | Past Directorships |
None | PL & JE Services Limited |
The Company confirms that there is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
Follow the stocks
